|
Morepen Laboratories Limited. The Group's principal activities are manufacturing and marketing generic bulk drugs. The products of the Group include Loratadine, Cisapride, Sulbactum Sodium, Sultamicillin Tosylate, Fluvastatin, Losartan, Zafirlucast and Montelucast, formulation dosage forms, consumer care products and herbal products.
The company was established in the year 1984, Morepen Laboratories is a fast growing Pharmaceutical company listed in all major stock exchanges in India including Bombay Stock Exchange (BSE) and National Stock Exchange (NSE) since 1993 with an Investor base of 62,400 shareholders. Top-notch financial institutions of the country like UTI, LIC and GIC are its investors since IPO. The company has an asset base of over USD 286 million and growing. Morepen has a progressive lineage of manufacturing high quality Generic drugs and Pharmaceutical formulations backed by a strong R&D, Regulatory and global marketing team.
The big thrust of Morepen's strategy is, focused on creating a new category in the Indian International pharmaceutical market vis a vis, Pharma Contract Manufacturing. Morepen today is the largest producer of Loratadine in the World and presently has, over 90% market share of generic Loratadine in the US market other than the Innovator by supplying the bulk drug to top class customers like Novartis, Merck etc. Morepen is the approved global supplier to these companies.
|
